title: Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles.
abstract: The purpose of the current study was to develop a controlled-release delivery system for recombinant insulin-like growth factor (rhIGF-I). Polylactide-co-glycolide (PLG) microparticles with entrapped rhIGF-I were prepared by a novel emulsion based solvent evaporation process. Microparticles with two loading levels of rhIGF-I were prepared (4 and 20% w/w). The integrity of released rhIGF-I was characterized by RP-HPLC, SDS-PAGE and a bioactivity assay. In vitro and in vivo release profiles of rhIGF-I from these microparticles were also evaluated. Reproducible batches of microparticles with 4% and 20% w/w loading of rhIGF-I were prepared, with excellent encapsulation efficiency (81 and 85% of total protein respectively entrapped). The protein retained integrity after the microencapsulation process as evaluated by RP-HPLC, SDS-PAGE and bioactivity assay. The in vitro profiles exhibited a significant burst release of rhIGF-I (20-30%), followed by controlled release of protein for up to 28 days. A similar level of burst release was observed in vivo, followed by controlled release of protein for 14-18 days. In addition, there was a surprisingly close correlation between in vitro and in vivo release rates. PLG microparticles with entrapped rhIGF-I are a promising delivery system which may allow rhIGF-I to be used for a broad range of therapeutic indications.
authors.affiliation: Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA. manmohan_singh@cc.chiron.com
authors.forename: M
authors.initials: M
authors.lastname: Singh
authors.forename: B
authors.initials: B
authors.lastname: Shirley
authors.forename: K
authors.initials: K
authors.lastname: Bajwa
authors.forename: E
authors.initials: E
authors.lastname: Samara
authors.forename: M
authors.initials: M
authors.lastname: Hora
authors.forename: D
authors.initials: D
authors.lastname: O'Hagan
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D019344:Lactic Acid / Q000008:administration & dosage*; D011100:Polyglycolic Acid / Q000008:administration & dosage*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D011108:Polymers; D011994:Recombinant Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D007334:Insulin-Like Growth Factor I